Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06630845 · ClinicalTrials.gov registry record · NA
Comparison of Whole Body DWI to FDG PET
A NA study of Metastatic Cancer, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06630845 is a NA study of Metastatic Cancer that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 30 participants, below the 444-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06630845, a NA study of Metastatic Cancer, is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single arm prospective trial that evaluates whole body diffusion weight imaging (DWI) compared to 18F-fludeoxyglucose (FDG) Positron Emission Tomography with Magnetic resonance imaging (PET/MRI) in participants with known metastatic cancer.
Conditions Studied
Interventions
- DRUG Fluorodeoxyglucose F18
- PROCEDURE Positron Emission Tomography combined with Magnetic resonance imaging (PET/MRI)
- PROCEDURE Whole Body Magnetic Resonance Imaging with Diffusion-Weighted Imaging (WB-MRI-DWI)
- DEVICE General Electric (GE) SIGNA PET/MR
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-02-06 |
| Est. Completion | 2029-10-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06630845
The ClinicalTrials.gov registry entry for NCT06630845 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 444-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (93% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Cancer appearing as the primary indexed condition, and to 4 interventions - of which Fluorodeoxyglucose F18 is the first listed.
NCT06630845 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06630845 about?
NCT06630845 is a clinical study titled "Comparison of Whole Body DWI to FDG PET". This is a single arm prospective trial that evaluates whole body diffusion weight imaging (DWI) compared to 18F-fludeoxyglucose (FDG) Positron Emission Tomography with Magnetic resonance imaging (PET/MRI) in participants with known metastatic cancer.
What is the current status of trial NCT06630845?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2025-02-06. Estimated completion is 2029-10-31.
What conditions does trial NCT06630845 study?
This clinical trial studies the following conditions: Metastatic Cancer.
What interventions are being tested in trial NCT06630845?
The interventions under investigation include: Fluorodeoxyglucose F18 (DRUG), Positron Emission Tomography combined with Magnetic resonance imaging (PET/MRI) (PROCEDURE), Whole Body Magnetic Resonance Imaging with Diffusion-Weighted Imaging (WB-MRI-DWI) (PROCEDURE), General Electric (GE) SIGNA PET/MR (DEVICE).
Who is sponsoring clinical trial NCT06630845?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06630845 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Longitudinal Screening for Financial Hardship to Improve Outcomes in Patients With Advanced Cancer
RECRUITING · NA
-
PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
RECRUITING · NA
-
A Study of the ApricityCare Program for Early Detection and Management of Treatment-Related Adverse Events in Patients With Cancer
RECRUITING · NA
-
Palliative Spatially Fractionated (GRID) Radiotherapy Using Intensity Modulated Proton Therapy
RECRUITING · NA
-
COBRA: Cancer, Older Adults, Balance and Resistance Activities
RECRUITING · NA
-
Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.